NCT01290549 - A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 22, 2011

Primary Completion Date

June 29, 2012

Study Completion Date

November 18, 2014

Conditions

Non-Hodgkins LymphomaChronic Lymphocytic Leukemia

Interventions

DRUG

Polatuzumab Vedotin

Participants will receive escalating intravenous dose of polatuzumab vedotin.

DRUG

Rituximab

Rituximab will be administered by an IV infusion at 375 mg/m\^2 body surface area dose q3w.

Trial Locations (16)

14263

Roswell Park Cancer Inst., Buffalo

21000

CHU Dijon - SCE Hemato, Dijon

34232

Florida Cancer Specialists; Sarasota, Sarasota

34295

CHU Lapeyronie, Hematologie, Montpellier

38138

Sarah Cannon Cancer Center, Germantown

69495

Centre Hospitalier Lyon Sud; Hematolgie, Pierre-Bénite

76038

Centre Henri Becquerel; Hematologie, Rouen

77030

M.D Anderson Cancer Center; Oncology, Houston

94305

Stanford Cancer Institute Pharmacy, Stanford

98109

Fred Hutchinson Cancer Research Center, Seattle

94305-5820

Stanford Cancer Center, Stanford

T6G 1Z2

Cross Cancer Institute ; Dept of Medical Oncology, Edmonton

V5Z 1H6

British Columbia Cancer Agency, Vancouver

H3T 1E2

McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal

Unknown

Centre Hospitalier Regional Universitaire de Lille, Lille

1105 AZ

Academisch Medisch Centrum; Hematologie, Amsterdam